2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Joyce A. O'Shaughnessy, MD, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.
Joyce A. O’Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center; Texas Oncology, PA/US Oncology, Dallas, Texas, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.
It is difficult to understand different types of triple-negative breast cancer (TNBC) today, O’Shaughnessy says, as there are no laboratory tests in this space. There are data coming out that show certain chemotherapy agents may be more effective for TNBC than they are for ER-positive disease.
O’Shaughnessy says that there are some subtype-specific differences with cytotoxic agents but we are still in the early days of research.